DPP1 Inhibitors
1 drugsAbout DPP1
Dipeptidyl peptidase 1 (DPP1) is an enzyme involved in the activation of serine proteases within immune cells. Inhibiting DPP1 modulates the activity of these proteases, impacting immune cell function.
DPP1 is a therapeutic target, evidenced by the FDA approval of BRINSUPRI. Currently, there is no genetic evidence directly linking DPP1 to specific diseases.
DPP1 is targeted by one FDA-approved drug, BRINSUPRI, a small molecule. INSMED INC is the sole company with an approved DPP1-targeting therapy, indicated for a non-common therapeutic area.
Top DPP1 Drugs
INSMED INC is the only company with an approved DPP1-targeting drug.
The lack of competitors indicates high barriers to entry or untapped potential.
DPP1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DPP1, using small molecule modality.
Exploring alternative modalities like antibodies could provide differentiation.
DPP1 Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DPP1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 8 | 0 | 1 | 100% |
| Phase 2 | 4 | 3 | 1 | 0 | 75% |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DPP1 Drug Approval Timeline (2025 - 2025)
The first and most recent DPP1-targeting drug, BRINSUPRI, was approved in 2025.
Recent approval suggests renewed interest, but market saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DPP1. A trial counts if an approved drug acting on DPP1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.